On Sept. 6, 2016, Danaher announced a merger agreement with Cepheid pursuant to which Danaher acquired all of the outstanding shares of Cepheid for $53.00 per share in cash, or a total enterprise value of approximately $4 billion including indebtedness and net of acquired cash.

Cepheid became part of Danaher’s Diagnostics segment, joining the Company’s Beckman Coulter, Leica Biosystems and Radiometer businesses.